Изберете език

bg
  • bg

  • cs

  • da

  • de

  • el

  • en

  • es

  • et

  • fr

  • hr

  • hu

  • it

  • lt

  • lv

  • nl

  • no

  • pl

  • pt

  • ro

  • ru

  • sk

  • sl

  • sv

  • tr

  • uk

Български
  • Български

  • Čeština

  • Danske

  • Deutsch

  • ελληνική

  • English

  • Español

  • Eesti keel

  • Français

  • Hrvatski

  • Magyar

  • Italiano

  • Lietuvių

  • Latviešu

  • Nederlands

  • Norsk

  • Polski

  • Português

  • Română

  • Русский

  • Slovenský

  • Slovenski

  • Svenska

  • Türkçe

  • Українська

Как предпочитате да зареждате своята сметка?

* Не начисляваме комисионна за депозиране на средства във вашата сметка

Sanofi

SAN.EU 92.44 EUR

0.49 € (0.53%)

Потенциал за растеж

Препоръката
се преразглежда

Доход от дивиденти

3.49%

1d
1w
1 мес.
6 м.
През цялото време

Добавяне в количката

1 лот = 1 акция

Закупено количество:

Брокерска комисионна:

Комисионна за прехвърляне:

Препоръка

Strong Buy

Рейтинг за ефективност

DCF

-

ROE

0.2

ROA

0.11

P/S

2.59

P/B

1.54

Debt / Equity

0.33

Относно компанията

Sanofi SA is a multinational pharma company headquartered in Paris, France. Since 2013, this is the world's fifth company by prescribed drug sales. Founded back in 1973, the company was re-structured and re-branded as Sanofi-Aventis in 2004, after the merger of Aventis and Sanofi-Synthélabo, each of both being a result of previous mergers. In May 2011, the company was renamed to Sanofi. The company works in the following fields: cardiovascular system, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines.

Sanofi concluded a few successful acquisitions, the largest being Zentiva, Shantha Biotechnics, Chattem, Medley Pharmaceuticals Ltd., Genzyme, Globalpharma, and Bioverativ.

In Q1 2020, Sanofi's net profit rose by 47% to reach €1.68B, compared to €1.14B in Q1 2019. The earnings soared by 6.90% to €8.973B, or 6.60% currency rate adjusted. The boost occurred thanks to Dupixent, a drug used for eczema and asthma treatment. Dupixent sales skyrocketed by 129.80% to reach €776M.

Meanwhile, the earnings per share soared by 15.60% (no currency rate adjustment) and is now €1.63. Sanofi is still expecting the EPS to rise by 5% more by the end of 2020. Finally, the company's market cap increased by 14.60% over the last month, to reach €111.50B.


Регистрирайте се за инвестиционни идеи от анализаторите на Freedom Finance

Веднъж седмично ще изпращаме имейл само с най-подходящата и важна информация

Поздравления!

Сега винаги ще знаете кои акции са по-доходоносни за инвестиция